SEC Form 4 · accession 0001209191-16-109316

Kite Pharma, Inc. · KITE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Jeffrey Wiezorek

Officer — SVP Clinical Development

Period of report

Mar 15, 2016

Accepted (ET)

Mar 17, 2016 · 9:15 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001510580

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Mar 15, 2016	M	9,000	$6.89	A	23,867	D
Common Stock^F3	Mar 15, 2016	S	6,742	$44.56	D	17,125	D
Common Stock^F4	Mar 15, 2016	S	1,538	$45.32	D	15,587	D
Common Stock^F5	Mar 15, 2016	S	461	$46.49	D	15,126	D
Common Stock^F6	Mar 15, 2016	S	259	$47.82	D	14,867	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)	$6.89	Mar 15, 2016	M	1,708	D	Nov 30, 2015	Jun 5, 2024	Common Stock	1,708	14,292	D
Employee Stock Option (Right to Buy)^F7	$6.89	Mar 15, 2016	M	7,292	D	—	Jun 5, 2024	Common Stock	7,292	86,708	D

Explanation of responses

F1Includes 1,125 shares acquired under the 2014 Employee Stock Purchase Plan on February 19, 2016.
F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2015.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.04 to $45.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.04 to $45.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.05 to $46.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.31 to $48.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F725% of the 175,000 shares subject to the stock option vested and became exercisable on May 5, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.